David Melamed, PhD,  —

SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat in combination with BCMA-targeting agents to treat people with relapsed or refractory multiple myeloma. The collaboration with Pfizer aims to test nirogacestat plus PF‐06863135 in a Phase 1b/2…

One of the most common genomic defects in multiple myeloma patients is the loss of one copy of chromosome 13, and researchers now suggest that the loss of one particular gene during that process initiates a cascade of cell division events that promotes myeloma progression. This gene codes for two microRNAs — …

A clinical trial is soon to begin testing Precision BioSciences‘s new CAR T-cell therapy candidate, PBCAR269A, in people with relapsed or refractory multiple myeloma. The Phase 1/2a trial (NCT04171843) is expected to begin enrolling eligible adults in March at multiple U.S. sites, the company said. Precision made the announcement after…

A recent partnership between Indapta Therapeutics and Lonza is advancing the development of an off-the-shelf cell therapy designed to treat multiple types of cancers, including multiple myeloma, the companies announced. The collaboration aims to ultimately guide this treatment from promising preclinical studies into clinical trials, with a first such study…

NexImmune will soon initiate a Phase 1/2 trial evaluating its cell therapy NEXI-002 in people with multiple myeloma who failed three or more prior lines of therapy, the company announced. The announcement comes after the U.S. Food and Drug Administration cleared NexImmune’s investigational new drug…